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Introduction: Although neoadjuvant chemotherapy (NAC) for locally advanced breast cancer can improve
operability and local disease control, there is a lack of reliable biomarkers that predict response to chemotherapy or
long-term survival. Since expression of aldehyde dehydrogenase-1 (ALDH1) is associated with the stem-like proper-
ties of self-renewal and innate chemoresistance in breast cancer, we asked whether expression in serial tumor sam-
ples treated with NAC could identify women more likely to benefit from this therapy.
Methods: Women with locally advanced breast cancer were randomly assigned to receive four cycles of
anthracycline-based chemotherapy, followed by four cycles of taxane therapy (Arm A), or the same regimen in
reverse order (Arm B). Tumor specimens were collected at baseline, after four cycles, and then at surgical resection.
ALDH1 expression was determined by immunohistochemistry and correlated with tumor response using Fisher’s
exact test while Kaplan-Meier method was used to calculate survival.
Results: A hundred and nineteen women were enrolled into the study. Fifty seven (48%) were randomized to Arm
A and 62 (52%) to Arm B. Most of the women (90%) had ductal carcinoma and 10% had lobular carcinoma. Of
these, 26 (22%) achieved a pathological complete response (pCR) after NAC. There was no correlation between
baseline ALDH1 expression and tumor grade, stage, hormone receptor, human epidermal growth factor receptor 2
(HER2) status and Ki67 index. ALDH1 negativity at baseline was significantly associated with pCR (P = 0.004). The
presence of ALDH1(+) cells in the residual tumor cells in non-responding women was strongly predictive of worse
overall survival (P = 0.024). Moreover, serial analysis of specimens from non-responders showed a marked increase in
tumor-specific ALDH1 expression (P = 0.028). Overall, there was no survival difference according to the chemotherapy
sequence. However, poorly responding tumours from women receiving docetaxel chemotherapy showed an
unexpected significant increase in ALDH1 expression.
Conclusions: ALDH1 expression is a useful predictor of chemoresistance. The up-regulation of ALDH1 after NAC
predicts poor survival in locally advanced breast cancer. Although the chemotherapy sequence had no effect on overall
prognosis, our results suggest that anthracycline-based chemotherapy may be more effective at targeting ALDH1(+)
breast cancer cells.
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The use of neoadjuvant chemotherapy (NAC) in women
with locally advanced breast cancer can reduce the tumor
size and improve the rates of breast conserving surgery
[1,2]. The degree of pathological response to NAC has
been shown to correlate with long-term prognosis [3-5],
although the precise definition of complete pathological
response (pCR) varies across different studies [6-8]. Typic-
ally, patients with high grade or triple negative tumors have
higher pCR to cytotoxic therapy and, conversely, failure to
achieve pCR clearly results in poor long-term outcomes
[9,10]. In addition, the utility of markers, such as estrogen
receptors (ER) and progesterone receptors (PR) status in
the neoadjuvant setting, is not clear, although human epi-
dermal growth factor receptor 2 (HER2) gene amplification
is associated with better response to neoadjuvant anti-
HER2 therapy [11,12]. Given the heterogeneity of breast
cancer at a phenotypic and molecular level, and the fact
that only 15 to 20% of patients achieve a pCR [13-15], bio-
markers that accurately predict a survival benefit from
NAC remain a pressing and unmet clinical need.
Aldehyde dehydrogenase-1 (ALDH1) is a cytosolic en-
zyme, responsible for the metabolism of intrace-
llular aldehydes [16]. Numerous preclinical studies haveFigure 1 Study design. Flowchart depicting the examinations, imaging m
breast cancer.shown that expression of ALDH1 in tumor cells has been
associated with stem-like characteristics, including innate
chemoresistance and clonal capacity [17-20]. Moreover,
expression of ALDH1 in surgically resected breast cancer
is strongly associated with metastasis and poor survival
[18,21]. Therefore, expression of ALDH1 may serve as a
marker of highly clonogenic, chemoresistant stem-like
cells that form the basis for recurrent disease in locally ad-
vanced breast cancer.
Since NAC protocols allow for the monitoring of re-
sponses to chemotherapy in a carefully controlled manner
by analyzing the pathologic response, we investigated
whether ALDH1 expression could serve as a useful bio-
marker in breast cancer treated with chemotherapy. In the
current study, we addressed the hypothesis that ALHD1
expression correlates with innate chemoresistance, and
that up-regulation of its expression following NAC can
predict recurrence and hence survival. We tested our hy-
pothesis by analyzing sequential tumor specimens taken
before, during and at the end of NAC in a large cohort of
patients treated in a prospective randomized clinical trial.
We also explored the prognostic role of different patho-
logical breast cancer subtypes, defined by immunohisto-
chemistry and correlated with ALDH1 expression.odalities and chemotherapy for women with locally advanced
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Study design
Women with locally advanced breast cancer (T1-T3, N0-
N3, M0) between April 2004 and December 2011 were in-
vited to participate in this study with inclusion criteria of
histologically confirmed invasive adenocarcinoma of the
breast, age >18, an Eastern Cooperative Oncology Group
(ECOG) performance status of 0 or 1, and adequate he-Table 1 Patient’s characteristic, overall and according




→ TAX No (%)
Arm B TAX
→ FEC No (%)
Total 119 (100) 62 (52) 57 (48)
Age
>50 67 (56) 22 (36) 30 (53)
≤50 52 (44) 40 (64) 27 (47)
Sex
Female 119 (100) 62 (100) 57 (100)
Male 0 (0) 0 (0) 0 (0)
T stage
T1 22 (18) 11 (18) 11 (19)
T2 78 (65) 41 (66) 37 (64)
T3 19 (17) 10 (16) 9 (17)
Nodal status
Positive 96 (81) 51 (82) 45 (78)
Negative 23 (19) 11 (18) 12 (22)
Histological type
IDC 108 (88.5) 57 (92) 51 (90)
ILD 11 (11.5) 5 (8) 6 (10)
Pathological grade
1 or 2 46 (39) 22 (36) 24 (42)
3 73 (61) 40 (65) 33 (58)
Breast cancer subtype
Luminal A 24 (20) 10 (16) 14 (24)
Luminal B 49 (41) 25 (40) 24 (42)
HER2 17 (14) 12 (19) 5 (9)
TN 29 (24) 15 (24) 14 (24)
Ki67 (N = 106)
>20% 68 (64) 31 (57) 37 (71)
≤20% 38 (36) 23 (43) 15 (29)
Surgery
Mastectomy 56 (47) 27 (44) 29 (51)
BCS 63 (53) 35 (56) 28 (49)
Response rates
pCR 26 (22) 14 (23) 12 (21)
non pCR 93 (78) 48 (77) 45 (79)
BCS, breast conserving surgery; FEC, fluorouracil, epirubicin,
cyclophosphamide; TAX, docetaxel; TN, triple negative.matological, renal, hepatic and cardiac function. Subjects
were excluded based on a prior history of other neoplasms
(except non-melanoma skin cancers), other serious med-
ical conditions, or concurrent participation in any other
investigational/experimental drug trial. The study was ap-
proved by the human research and ethics committees at
all the participating institutions (Monash Medical Centre,Table 2 Univariable and multivariable analysis of response
rates according to various prognostic groups (N = 119)
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TN 41(TN vs. others) 0.008 0.033 3.41 (1.10
to 10.86)








Negative 32 0.007 0.004 5.76 (1.76
to 18.45)
ALDH1, aldehyde dehydrogenase-1; HER2, human epidermal growth factor
receptor 2; IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma; TN,
triple negative.
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Australia) and all participating women provided written
and informed consent.
Subjects were randomized to receive either four cycles of
FEC100 (fluorouracil 500 mg/m2, epirubicin 100 mg/m2
and cyclophosphamide 500 mg/m2) followed by four cycles
of docetaxel (100 mg /m2), (Arm A), or the same therapy
in reverse order (docetaxel × 4 followed by FEC100 × 4)
(Arm B). Each patient received a total of eight, three-
weekly cycles over a period of 24 weeks.
All women underwent a clinical examination, mam-
mography, ultrasound and a tumor core biopsy at base-
line (within four weeks prior to the commencement of
chemotherapy). All assessments were then repeated after
four cycles of chemotherapy (FEC100 or docetaxel) and
again at the completion of eight cycles (Figure 1). Fur-
ther periodic clinical assessments after each cycle ofFigure 2 Representative immunohistochemical staining intensity of A
(B) ALDH1 positive (1+), (C) = ALDH1 positive (2+) and (D) ALDH1 positive
tumor stroma in some cases (F). Only cytoplasmic staining in the invasive t
dehydrogenase-1.chemotherapy were performed to ensure that the tumor
was not progressing. All imaging and core biopsies were
performed at the same center.
Specimen collection
Tumor specimens were obtained from each patient at three
different time points (Figure 1). The first ultrasound-guided
core biopsy was taken at baseline, before any chemotherapy
and a second core biopsy was performed after four cycles of
chemotherapy. The third sample was obtained from the final
surgical excision sample. Each specimen was fixed in 10%
formaldehyde and embedded in paraffin. Hematoxylin and
eosin (H&E) stained sections were analyzed by an experi-
enced anatomical pathologist, in order to determine tumor
type, grade, extent and tissue quality. Each tumor specimen
was stained with standard antibodies for the expression of
ER, PR, HER2 and Ki67 in accordance with local clinicalLDH1 for patients with breast cancer. (A) ALDH1 negative (0) result,
(3+). Strong staining was also observed on the normal ducts (E) and
umor component was considered for final analysis. ALDH1, aldehyde
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situ hybridization technique using the INFORM HER2 Dual
ISH DNA Probe (VentanaW Medical System, Tucson, AZ,
USA). Scoring for HER2 was performed as per American
Society of Clinical Oncology/College of American Patholo-
gists (ASCO/CAP) guidelines [22].
Breast cancer subtypes
We divided ER+ tumors into either luminal A (Her2−/
Ki67low) or luminal B (HER2+ or Ki67high) subtypes, as previ-
ously described [23]. All ER− and HER2+ were classified as
HER2 subtype, while ER−/PR−/HER2− was classified as a triple
negative subtype [24].Table 3 Correlation of ALDH1 with other prognostic markers
Variable Total No (%) ALDH1 (+) No (%) P-value
Total 119 (100) 56 (47)
Age 0.100
>50 67 (56) 25 (37)
≤50 52 (44) 31 (59)
T stage
T1 22 (18) 9 (40)
T2 78 (65) 38 (49)
T3 19 (17) 8 (42) 0.985
Nodal status
Positive 96 (81) 46 (50)
Negative 23 (19) 8 (38) 0.455
Histological type
IDC 108 (88.5) 52 (48)
ILD 11 (11.5) 4 (36) 0.537
Pathological grade
1 or 2 46 (39) 22 (48)
3 73 (61) 34 (46) 0.395
Breast cancer subtype
Luminal A 24 (20) 10 (41)
Luminal B 49 (40) 20 (41)
HER2 17 (14) 10 (59)
TN 29 (24) 16 (55) 0.431
Ki67 (N = 106)
>20% 68 (64) 29 (58)
≤20% 38 (36) 21 (42) 0.311
Surgery
Mastectomy 56 (47) 21 (37)
BCS 63 (53) 35 (55) 0.066
Response
pCR 26 (22) 6 (23)
Non-pCR 93 (78) 50 (54) 0.007
ALDH1, aldehyde dehydrogenase-1; pCR, pathologic complete response; HER2,
human epidermal growth factor receptor 2; IDC, invasive ductal carcinoma;
ILC, invasive lobular carcinoma; TN, triple negative.Immunohistochemistry
The staining for ALDH1 (Vector Laboratories, Burlingame,
CA, USA) was performed using Vectastain Ellite ABC kit
according to the manufacturer’s recommendations. For
ALDH1 staining, we used commercially available and previ-
ously established monoclonal antibody (clone 44/ALD. BD
Biosciences, dilution 1:200) that reliably detects ALDH1 and
its isoform ALDH1A1 [25].
All the sections were deparaffinized in xylene and rehy-
drated in ethanol. Antigen retrieval was performed by micro-
waving the slides in citrate buffer (pH 6.0) for 10 minutes.
Endogenous peroxidase activity was blocked by 15-minute
incubation in 1% hydrogen peroxide. A protein block with a
10% normal serum was performed for 30 minutes. Incuba-
tion with primary antibody was carried out at 4°C overnight.
The secondary antibody was applied for 30 minutes, after
washing with tris-buffered saline (TBS). Diaminobezadine so-
lution was used for color detection, followed by counterstain-
ing with hematoxylin. All staining runs were accompanied
by appropriate control slides (normal human liver sections).
Scoring of ALDH1 expression
All the stained slides were scanned into a digital slide
scanner (APERIO Scan ScopeXT®, San Diego, CA, USA)
and eSlides were created. Magnification of up to 40X was
achieved for each section. Two pathologists independently
evaluated all the scanned sections in a blinded manner.
Whole tumor sections were analyzed thoroughly to look
for tumor-specific ALDH1 expression. The ratio of posi-
tive to negative cellular profiles was estimated as a per-
centage of all tumor cells in a slide. The intensity of
the staining was also assessed as follows; 0 = no staining,
1 =mild staining, 2 =moderate staining and 3 = strong
staining. A histological H-score was obtained by multiply-
ing the percentage of staining with the intensity, thus
obtaining an overall score ranging from 0 to 300. In order
to classify patients into ALDH1(+) and ALDH1(−) groups,
we used the previously published criteria, which was 3+
(≥50% positive tumor cells), 2+ (<50% to ≥10%), 1+ (<10%to ≥5%) and 0 (<5%). For the analysis, all 1+, 2+ and 3+
were considered positive [18,26].Pathologic response
A pathological response in the final resected specimens
was used as the definitive outcome measure by assessing
residual cancer cellularity in all the specimens. A complete
pathological response was defined as a complete absence
of tumor in the resected primary tumor as well as in the
lymph nodes [9].
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All tumors and involved axillary nodes were evaluated
clinically, by imaging with mammography, ultrasound and
fludeoxyglucose-positron emission tomography (FDG-
PET) scans at baseline, at the midpoint and at the end of
chemotherapy, that is, before surgery. MRI scans were
obtained at baseline and at the end of chemotherapy.
In this report, only the relevant pathologic data are
reviewed.Statistical analysis
All analyses were carried out using SPSS, version 21
(SPSS Inc., Chicago, IL, USA). The ALDH1 H-score was
compared among patient’s demographic characteristics
and baseline tumor characteristics using the Mann–
Whitney U test. Sequential changes in ALDH1 H-scores
in the corresponding tumor specimens obtained at base-
line, at midpoint and at the end of chemotherapy were an-
alyzed using the Kruskal-Wallis test. Patients were also
dichotomized into ALDH1(+) and ALDH1(−) groups
based on cut-off points as described above. Tumor re-
sponse rates as well as other clinicopathological parameters
were compare among ALDH1(+) and ALDH1(−) groups
using Fisher’s exact or Chi square tests, depending on the
data characteristics. Overall survival (OS) was defined as
the duration (in months) between date of randomization
and date of death (due to breast cancer). The Kaplan-Meier
method was used to plot the survival curves and the log
rank test was used to estimate the statistical difference be-
tween the two groups. A Cox proportional hazard model
was used to carry out group comparison while the propor-
tional hazard assumption assessment was performed graph-
ically by plotting cumulative hazard functions for theFigure 3 Overall survival analysis according to ALDH1 expression pre
prognostic significance of ALDH1 pre and post neo-adjuvant chemotherap
chemotherapy, there was no significant difference in overall survival in ALD
who were ALDH1(−) had much better overall survival (100% five-year survi
(P = 0.045, HR 3.75, 95% CI 1.03 to 14.42). ALDH1, aldehyde dehydrogenasecovariates. A P-value (two-tailed) of <0.05 was considered
statistically significant.
Results
One hundred and thirty four patients were recruited into
the study between April 2004 and December 2011. Of
these patients, two withdrew and a further nine were
found to have computed tomography (CT) occult distant
metastases on FDG-PET imaging, which were confirmed
on biopsies. Tumor core biopsies were successfully ob-
tained in 123 patients at the baseline, and from 116 pa-
tients at the midpoint of treatment. Baseline core
biopsies from four patients contained inadequate tissue
for ALDH1 staining and were excluded, leaving a total
of 119 informative subjects. Sixty three (53%) patients
underwent breast-conserving surgery. All patients were
female and most had invasive ductal cancer (108/119,
90%). The majority of the patients had high grade (73/
119, 61%) and node-positive (96/119, 81%) tumors. Most
of the tumors were positive for estrogen receptors (73/
119, 61%) while 30% (36/119) were HER2 positive and
24% (29/119) had a triple negative phenotype. Detailed
patient demographics and tumor characteristics of all
119 eligible patients according to the treatment arms are
shown in Table 1. All ER positive patients received adju-
vant endocrine treatment (tamoxifen or aromatase in-
hibitors) for at least five years and all HER2 positive
patients received trastuzumab for 12 months. All pa-
tients received adjuvant radiotherapy to the breast, chest
wall and axillary nodes. There was no significant differ-
ence in any of the demographic characteristics of the pa-
tients in the two chemotherapy arms.
A complete pathological complete response was ob-
served in 26/119 (22%) of patients, while 93/119 (78%)- and post-chemotherapy. The Kaplan-Meier curves illustrate the
y (NAC) in patients with locally advanced breast cancer. (A) Before
H1(−) vs. ALDH1(+) groups. (B) At the end of chemotherapy, patients
val) compared to those who were ALDH1(+) (66.5% five-year survival).
-1.
Figure 4 Prognostic significance of residual tumor at the end of NAC. These Kaplan-Meier curves depict that at the end of NAC, patients
with complete pathological response (pCR) (blue line in A) had much better OS compared to those with a residual tumor at the end of NAC
(green line in A). Surprisingly, patients with ALDH1(−) residual tumors at the end of NAC (purple line in A) also had much better OS. When
combined into one group (purple line in B), patients with no residual tumor or ALDH1(−) residual tumor had significantly better OS compared
to those with an ALDH1(+) residual tumor at the end of NAC (P = 0.005, HR 10.58, 95% CI 1.65 to 14.68). ALDH1, aldehyde dehydrogenase-1; NAC,
neoadjuvant chemotherapy; OS, overall survival.
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were 23 relapses (19%) and 19 (16%) breast cancer re-
lated deaths in the whole cohort. Univariable and multi-
variable analyses of response rates according to various
prognostic groups are shown in Table 2. As expected,
high grade or triple negative tumor type was significantly
associated with pCR (P = 0.002 and 0.033, respectively).
None of the 11 patients with invasive lobular carcinoma




(A vs. B) 1.56 (0.60 to 4.16)
Age (>50 vs. ≤50) 1.45 (0.56 to 3.75)
IDC vs. ILC 1.34 (0.45 to 5.49)
Grade (3 vs1/2) 1.79 (0.67 to 4.81)
ER (+) vs. (−) 0.53 (0.21 to 1.35)
PR (+) vs. (−) 0.31 (0.11 to 0.89)
HER2 (+) vs. (−) 1.22 (0.45 to 3.26)
TN (yes) vs. (no) 1.75 (0.65 to 4.65)
Ki67 (High) vs. (Low) 1.47 (0.50 to 4.16)
pCR vs. non pCR 2.21 (0.88 to 6.64)
ALDH1 (+) vs. (−)
Baseline 1.10 (0.43 to 2.81)
Post NAC* 10.58 (1.65 to 14.68)
ALDH1, aldehyde dehydrogenase-1; pCR, complete pathologic response; ER, estroge
ductal carcinoma; ILC, invasive lobular carcinoma; PR, progesterone receptor; TN, triExpression of ALDH1
Cytoplasmic ALDH1 staining was observed in the tumor
cells, tumor stroma as well as in the areas of in situ carcin-
oma. Strong ALDH1 staining was observed at the bifur-
cation of the terminal duct lobular unit (TDLU) of the
normal ductal epithelium, where stem cells are believed to
reside [18]. Tumors staining positive for ADLH1 observed
on the invasive cancer component of their tumor were con-
sidered positive, while staining in the stroma, areas of ductalg to various prognostic groups
Multivariable analysis










0.080 1.42 (0.08 to 2.32) 0.801
0.831
0.005 4.61 (1.30 to 23.00) 0.024
n receptor; HER2, human epidermal growth factor receptor 2; IDC, invasive
ple negative. *Post NAC, patients include ALDH1(−) as well as those with pCR.
Figure 5 Illustration of chemoresistance in ALDH1(+) tumors.
(A) Patients who did not have pCR to NAC, there was a statistically
significant rise in median ALDH1 H-score at midpoint (after four
cycles) as well as at the end (after eight cycles) of NAC. (B) Patients
who achieved pCR could not be stained for ALDH1 due to lack of
tumor cells at the end of eight cycles; however, after four cycles,
there was no significant rise in median ALDH1 H-score. Horizontal
bars indicate median H score (red) with 10th to 90th percentile
(black). (* = P-value <0.05, Kruskal Wallis test). ALDH1, aldehyde
dehydrogenase-1; pCR, complete pathologic response; NAC,
neoadjuvant chemotherapy.
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baseline, 56 (47%) patients were ALDH1+; however, only
eight patients (7%) showed 3+ (≥50% positive tumor cells)
staining. Representative sections are shown in Figure 2.
The correlation of ALDH1 expression at baseline accord-
ing to various prognostic groups is shown in Table 3. There
was no significant association of ALDH1(+) cases with any
other parameters, such as patients’ age, tumor stage, tumor
grade or breast cancer subtype, though there were relatively
higher ALDH1(+) cases in HER2 (59%) and triple nega-
tive (55%) subtypes compared to luminal subtypes (41%).
Moreover, there was no significant difference in baseline
ALDH1 expression when comparing the two chemotherapy
arms.
Baseline ALDH1 and response to NAC
Low level expression of ALDH1 in baseline biopsy sam-
ples strongly correlated with pCR following NAC, with
pCR rates of 32% in ALDH1(−) tumors compared to only
10% in ALDH1(+) tumors (P = 0.007). In multivariable
analysis, negative baseline ALDH1 status was independ-
ently associated with complete pathological response to
NAC (P = 0.004, Odds Ratio 5.76, 95% CI 1.76 to 18.45).
These data support similar findings previously reported in
breast cancer, suggesting that the expression of ALDH1 is
a marker of innate chemoresistance [26]. Patients with
high grade tumors or triple negative tumors also achieved
significantly higher pCR rates with P-values of 0.002 and
0.033, respectively (Table 2).
Expression of ALDH1 as a prognostic factor in locally
advanced breast cancer
The prognostic value of ALDH1 was calculated using
Kaplan-Meier survival analysis. The results showed that
baseline ALDH1 expression was not associated with OS
(P = 0.831). Patients achieving complete pathological re-
sponse to NAC showed a non-significant trend towards
better OS (P = 0.08). Although baseline ALDH1 expres-
sion was associated with a response to NAC, it did not
predict a long-term prognosis (Figure 3). Interestingly,
in women whose tumors were negative for ALDH1 at
the conclusion of NAC, OS was remarkably greater than
those with residual ALDH1(+) disease (P = 0.045) and
was almost similar to those achieving a pCR (Figures 3
and 4). In multivariable analysis, neither pCR nor
ALDH1(−) residual tumor was a predictor of OS, pos-
sibly due to a fewer number of patients. However, when
combined into one group, patients with ALDH1(−) tu-
mors at the conclusion of NAC and those achieving pCR,
had significantly greater OS compared with those having
ALDH1(+) residual disease (P = 0.005). In multivariable
analysis, this effect was seen independently of patients’
age, tumor stage, tumor grade or chemotherapy sequence
(Table 4), and the data suggest that an ALDH1(+) residualtumor at the end of chemotherapy is an independent
prognostic factor for survival in locally advanced breast
cancer (P = 0.024, HR 4.61 95% CI = 1.30 to 23.00).Sequential changes in ALDH1 expression following NAC
For this analysis, we divided the patients into two groups,
those who achieved a pCR such that ALDH1 expression
could not be assessed at surgery, and those with residual
tumor cells and informative ALDH staining (76 cases). Of
those, 50 tumors (66%) were ALDH1(+), with 26% show-
ing strong (3+) staining. In patients who did not achieve
a pCR, there was a significant rise in ALDH1 expres-
sion following NAC chemotherapy compared to baseline
(P = 0.028, Kruskal Wallis test) (Figure 5).
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response rates
Since we were unable to assess tumor ALDH1 expression
in patients achieving a pCR, we next analyzed the core
samples obtained at the study midpoint following four cy-
cles of either FEC or docetaxel. Of the 116 patients who
underwent tumor core biopsy at midpoint, 24 (21%) had
no residual tumors. The remaining 92 (79%) patient sam-
ples were stained for ALDH1, 45 (49%) were ALDH1(+).
We also observed phenotypic switching in some cases in
response to chemotherapy (Figure 6A,C). Of 55 ALDH1
(−) cases, some (N = 15, 27%) became ALDH1(+), while
the majority (N = 40, 73%) remained ALDH1(−). Similarly,
in the ALDH1(+) group (N = 37), the majority (N = 30,
81%) remained ALDH1(+) while seven patients (19%) be-
came ALDH1(−). When combined into one group, pa-
tients with ALDH1(+) tumors, either at baseline or at
midpoint, had pCR rates that were much worse compared
to those who remained ALDH1(−) at both points (37% vs.
16%, P = 0.019) (Figure 6B). Remarkably, patients whose tu-
mors remained negative at baseline, midpoint and followingFigure 6 Illustration of phenotypic switching in response to chemoth
during NAC. Chart A illustrates that there was a switch from ALDH1(−) to A
(+) to ALDH1(−) phenotype (negative switch) in 19% of cases, after four cy
both at baseline and after four cycles had the highest response rates, while
response rates. Those who were ALDH1(+) at any time point had intermed
patients receiving docetaxel (TAX) and a negative switch more often in pat
patients who remained ALDH1(−) throughout the eight cycles of NAC was
(D). (* = P <0.05 Fishers exact test). ALDH1, aldehyde dehydrogenase-1; FEC
chemotherapy.completion of NAC had significantly better outcomes des-
pite failing to achieve a pCR (Figure 6D).
Effect of chemotherapy type on ALDH1 expression and
tumor response
To observe the chemotherapy effect on ALDH1 expression
we again focused on the changes in ALDH1 expression be-
tween baseline and midpoint samples, and compared the
effects of FEC vs. docetaxel on the expression of ALDH1.
Unexpectedly, we observed a significant increase in the me-
dian ALDH1 H-score in patients who received docetaxel
first (P = 0.029, Mann Whitney U test) (Figure 7), whereas
tumor samples from patients who had received FEC
showed no significant difference between ALDH1 ex-
pressions. A similar effect was observed in samples from
patients who did not achieve a pCR following the full cycles
of treatment. Here, tumors from subjects treated with doce-
taxel in the last four cycles displayed a significant increase
in the median ALDH1 score in the final specimen com-
pared to at the midpoint (P = 0.002). Once again, this effect
was not seen in tumors treated with FEC chemotherapyerapy. Dynamic changes in the expression of ALDH1 were observed
LDH1(+) phenotype (positive switch) in 27% of cases and from ALDH1
cles of chemotherapy. However, patients who remained ALDH1(−)
those who were ALDH1(+) at both time points had the lowest
iate response rates (B). We observed a positive switch more often on
ients receiving FEC chemotherapy (C). Finally, the overall survival of
significantly higher than those who were ALDH1(+) at any time point
, fluorouracil, epirubicin, cyclophosphamide; NAC, neoadjuvant
Figure 7 The effect of chemotherapy type on ALDH1 expression. There was a significant rise in median ALDH1 H-score after docetaxel (TAX)
therapy, whether received at the beginning (A) or after four cycles of FEC (B). Conversely, there was no significant change in the median H-score
after FEC, whether received at the beginning or after four cycles of docetaxel (TAX). Horizontal bars indicate median H score (red) with 10th to 90th
percentile (black). (* = P-value <0.05, Mann–Whitney U test). ALDH1, aldehyde dehydrogenase-1; FEC, fluorouracil, epirubicin, cyclophosphamide.
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http://breast-cancer-research.com/content/16/2/R44following docetaxel (P = 0.308). Moreover, when we ex-
plored the phenotypic switching according to the chemo-
therapy type, we observed that the switching from ALDH1
(−) to ALDH1(+) phenotype was more often seen in tumor
samples after four cycles of docetaxel (23%) compared to
those receiving four cycles of FEC (10%). The opposite
phenomenon was observed more often in the FEC group
(20%) compared to the docetaxel group (10%) (P = 0.040,
Fisher’s exact test).Discussion
In a large cohort of women with locally advanced breast
cancer treated with NAC, we have shown that expression of
ALDH1, a marker of stem-like cancer cells, strongly predicts
for innate resistance to sequential FEC/TAX chemotherapy.
These findings are in keeping with those of Tanei et al.,
who reported that in 108 patients with locally advanced
breast cancer, treated with taxane/anthracyline-based NAC,
ALDH1(+) tumors were significantly associated with low
Alamgeer et al. Breast Cancer Research 2014, 16:R44 Page 11 of 13
http://breast-cancer-research.com/content/16/2/R44pCR rates [26]. This finding also supports the conclusions of
preclinical studies showing that ALDH1 expression and/or
activity marks breast cancer cells with an innate ability to
evade chemotherapy, and a markedly enhanced capacity
for tumor regeneration in vitro and in vivo [18,27].
Surprisingly, we showed that while ALDH1 expression
in baseline tumor samples is associated with primary re-
sistance to NAC, it does not predict long-term survival.
However, we showed that women in whom residual
tumor cells remained, ALDH1(−) derived a major sur-
vival benefit. Moreover, when the group of women who
achieved a pCR was combined with those with ALDH1
(−) tumors at the end of NAC, this group also derived a
highly significant survival advantage. Previous similar
studies were limited by a retrospective study design and
hence variation in results and difficulty in comparing the
study outcomes [28,29]. To our knowledge, this is the
first time that a biomarker of OS in residual tumor cells
that predicts OS in NAC patients has been described in
a prospective randomized study. A comparison of major
studies [26-30] in locally advanced breast cancer investi-
gating the predictive and prognostic significance of
ALDH1 is summarized in Table 5.
Our results show that although patients with ALDH1
(+) tumors at baseline display higher chemoresistance
than those with ALDH1(−) tumors, ALDH1(−) cases can
still convert to ALDH1(+) after chemotherapy and im-
pact the long-term prognosis. This phenomenon can be
explained by the likely possibility of the existence of a
tiny population (<5%) of ADLH1(+) cells which wouldTable 5 Summary of major studies investigating the clinical s
Study Chemotherapy No Antibody AL
Tanie et al. 2009 [26] Paclitaxel→ FEC 108 BD ≥5
Gong et al. 2010 [27] FEC 192 Abcam ≥2
Sakakibara et al. 2011 [28] AC→ paclitaxel 115 BD ≥5
Lee et al. 2011 [29] AD or AC 92 BD ≥5
Resetkova et al. 2009 [30] Anthracycline/paclitaxel 34 BD An
Current study FEC→ TAX Or TAX→ FEC 119 BD ≥5
There was consistency among most of the studies in terms of the primary antibody
the differences in study designs and/or patients’ population.
AC, adriamycin (doxorubicin), cyclophosphamide; DFS, disease free survival; FEC, flu
overall survival; TAX, docetaxel.have been scored as ALDH1(−) in the baseline samples.
Because ALDH1(+) cells are chemoresistant, they could
expand at the expanse of their relatively chemosensitive
counterparts. Another possible mechanism that can sus-
tain and hence propagate the ALDH1(+) stem cell pool
is believed to be the autocrine production of inflamma-
tory cytokines, such as interleukin 6 (IL-6) and interleukin
8 (IL-8), secondary to chemotherapy induced cellular
apoptosis [31,32]. The role of IL-6 and IL-8 in the self-
renewal of breast cancer stem cells has been extensively
studied [33]. Through the activation of STAT-3 and in
turn nuclear factor kappa B (NF-κB) signaling in inflam-
matory cells, these cytokines generate a positive feedback
loop between tumor stem cells and immune cells, thus
promoting cancer stem cells self-renewal and tumor
growth [34]. Interestingly, some initially ALDH1(+) cases
also converted to ALDH1(−) after chemotherapy and,
hence, achieved improvement in their long-term outcome.
These results may support a rare phenomenon of ‘pheno-
typic switching’, which indicates that stem cell-like and
non-stem cell-like populations in breast cancer may be
plastic and interconvertible. This phenomenon of cellular
plasticity has previously been described in preclinical
models [35]. However, this is the first description of the
clinical impact of dynamic conversion between marker-
defined stem cell-like and non-stem cell-like subpopula-
tions in breast cancer.
This study also demonstrated for the first time that dif-
ferent chemotherapeutic drugs could affect the expression
of ALDH1 and subsequent changes in sequential tumorignificance of ALDH1 in locally advance breast cancer
DH1 cutoff % positive Main results
% 19 • ALDH1(+) but not CD44+/CD24- phenotype
is associated with chemoresistance
0% 19.8 • ALDH1 at baseline correlated with clinical
response (CR/PR) and OS
% 39 • ALDH1(+) cells in residual axillary nodes is
associated with poor prognosis
% 13 • ALDH1(+) but not ALDH1(−) cases had
high pCR
• Increase in ALDH1 after NAC is associated
with poor DFS
y 56 • Stromal but not the tumor expression of
ALDH1 is prognostic in breast cancer.
% 47 • Pre NAC, ALDH1(+) is associated with poor
pCR rates
• Post NAC, ALDH1(+) cells in residual primary
tumor is prognostic
• Degree of chemoresistance may be different
for different chemotherapy types
used and cut-off point utilization. Variation in results could be explained by
orouracil, epirubicin, cyclophosphamide; NAC, neoadjuvant chemotherapy; OS,
Alamgeer et al. Breast Cancer Research 2014, 16:R44 Page 12 of 13
http://breast-cancer-research.com/content/16/2/R44specimens. While there was no difference in the baseline
ALDH1 expression in the two groups, patients who re-
ceived docetaxel and did not respond to treatment,
showed more enrichment for ADLH1 expression com-
pared to those who received FEC. Similarly, a significantly
higher number of patients switched from ALDH1(−) to
ALDH1(+) phenotype post-docetaxel compared to post-
FEC. These results suggest that a subgroup of ALDH1(+)
patients may receive more benefit from continuing
anthracyline-based therapy. However, a further larger
study may be needed to prove this hypothesis.
Conclusions
Our results indicate that ALDH1 is a marker of che-
moresistance in locally advanced breast cancer. Enrich-
ment of ALDH1 expression after chemotherapy in non-
responding patients suggests self-renewal potential of
cancer stem-like cells. However, dynamic changes in
ALDH1 expression in response to chemotherapy are a
more accurate predictor of long-term survival. Patients
remaining ALDH1(+) at the end of chemotherapy have
much worse prognosis. The dynamic changes in ALDH1
expression mirror the phenomenon of cellular plasticity
where phenotypic switching from ALDH1(+) to ALDH1
(−) phenotype or vice versa may depend on the type of
chemotherapy used.
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